glp 1 therapies How to use GLP-1 receptor agonist therapy safely and effectively Rethinking GLP-1RA Therapy Through the

Not many skin supplements proved to be efficacious after undergoing rigorous clinical trials by a recognized institution

5 Lower doses: Eight in ten real-world patients were on maintenance doses below 1.7 mg of semaglutide or 10 mg of tirzepatide

In a retrospective analysis of 182 patients with MDS with various subtypes, the multivariate analysis revealed a significant benefit in OS for patients receiving ICT with 140.9 months vs 36.3 months (p=0.0008) in case of refractory anemia (RA or, according to the present WHO classification: MDS-RS), 133.4 months vs 73.3 months (p=0.02) in case of refractory anemia with ring sideroblasts (RARS/RARS-t, corresponding to MDS-RS according to the present WHO classification) and no difference for refractory cytopenia with multilineage dysplasia (RCMD/RCMD-RS, corresponding to MDS-MLD according to the present WHO classification) (146)

10.1016/0002-8703(95)90192-2 272 TangX.-L.MccayP